Evaluating Clinical Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutated Metastatic Non-Small Cell Lung Cancer A Prospective Observational Study
Led by Daiichi Sankyo · Updated on 2026-08-18
150
Participants Needed
36
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the real-world effectiveness and safety of Trastuzumab Deruxtecan T-DXd in Chinese patients with locally advanced or metastatic non-small cell lung cancer NSCLC who have HER2 mutations. Although T-DXd is approved and has shown efficacy in clinical trials for NSCLC patients with these mutations, there is limited data on its use outside clinical trial settings in China.
This is a non-interventional, observational study where no study drug will be provided or administered by the study team. Participants who have already received T-DXd as part of their routine care, based on their physicians decision, will be enrolled and observed. The study focuses on patients receiving T-DXd as at least a second-line treatment.
Participants will be followed for up to approximately two years, during which researchers will collect information on progression-free survival, overall survival, treatment responses, and any treatment-related side effects. Data collection will include assessments by investigators and monitoring of adverse events to evaluate safety and tolerability in a real-world setting.
CONDITIONS
Brief Title
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
Research Team
C
Contact for Clinical Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Pathologically documented unresectable and/or metastatic non-squamous non-small cell lung cancer
Documented activating HER2 mutation
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Receiving Trastuzumab Deruxtecan (T-DXd) treatment based on physician's decision, started within 2 months before enrollment or newly started
You will not qualify if you...
Prior treatment with HER2-targeted therapies, including HER2-specific tyrosine kinase inhibitors (except pan-HER class TKIs) or antibody-drug conjugates targeting topoisomerase I
Presence of spinal cord compression or active central nervous system metastases that are untreated, symptomatic, or require corticosteroids or anticonvulsants
Evidence of severe or uncontrolled systemic diseases such as uncontrolled hypertension or active bleeding disorders
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Observation
Duration - Up to approximately 2 years
Participants receiving Trastuzumab Deruxtecan as part of their routine care are observed. Researchers collect data on treatment effectiveness, safety, and patient health over time.
Regular assessments and data collection visits
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Using 3-D Virtual Lung Resection to Predict Lung Function After VATS Surgery for Non-Small Cell Lung Cancer
Early Evaluation of Neoadjuvant Immunotherapy Response
Using 68Ga-grazytracer PETCT in Resectable Non-Small Cell Lung Cancer
Patients Aged 18 to 75 Years
Evaluating Calderasib with Subcutaneous Pembrolizumab Versus Pembrolizumab Plus Chemotherapy
for KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer
Randomized Study of Adjuvant Cemiplimab Versus Observation in Patients With Surgically Removed Stage II-IIIA Non-Small Cell Lung Cancer Without Prior Chemotherapy
Evaluating Adjuvant Intismeran With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa Compared to Placebo in High-Risk Stage I Non-Small Cell Lung Cancer
Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in People With Locally Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer After Chemoradiotherapy
Phase 2 Study of TQB2102 Injection for Treating Locally Advanced or Metastatic Non-Small Cell Lung Cancer with HER2 Gene Abnormality
Phase I Study of Intravenous CEA-Targeted CAR-T Therapy for Advanced CEA Positive Solid Tumors
Testing Safety and Effectiveness of BNT326 and Pumitamig Combination Therapy in Advanced Non-small Cell Lung Cancer
Phase IIIb Study to Evaluate the Safety and Effectiveness of Vebreltinib PLB1001 in Adults With Advanced or Metastatic Non-Small Cell Lung Cancer Having MET Exon 14 Mutation
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer (RERUN): Study Protocol for a Real-World, Multicenter, Prospective, Observational Study.